Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Long-term Investments

Investments the company intends to hold for more than a year.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Long-term Investments · Q2 FY2026 · quarter ended Jun 2026

Long-term investments falls 23.3% from a year ago

Long-term investments stood at $156.87M at the end of Q2 FY2026, down 23.3% from a year earlier and up 18.1% from the prior quarter. Over 3 fiscal years it compounded at +294.1% a year.

Context

  • Long-term investments amounted to 7.2% of total assets at the end of Q2 FY2026, down 14.4 pp from a year earlier.
  • Long-term investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps falling in the next quarterly balance sheet after a -23.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$156.87M+18.1% QoQ
Last fiscal yearDec 2025
$183.58M+1583.0% YoY
Year agoJun 2025
$204.46M-23.3% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.3%——
1 year+1583.0%——
3-year CAGR+294.1%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
183.58M USD
Year-over-year change
+1583.0%

Long-term Investments vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's Jun 2026 long-term investments of $156.87M is the 5th highest of the 10 companies compared; the peer median is $104.39M.
  • Its year-over-year change of -23.3% is the 6th highest of 9, against a peer median of -11.3%.
  • Long-term investments amounts to 7.2% of total assets for LGND, versus a peer median of 0.3%.
LGND Competitors Peer median
Long-term Investments for LGND and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PFEPfizer Inc.Jun 2026$1.56B +596.0%-51.3%0.8%
EXELExelixis, Inc.Jul 2026$544.93M -8.4%-7.3%21.8%
BMYBristol-Myers Squibb CompanyJun 2026$397M -82.4%+4.7%0.5%
ABBVAbbVie Inc.Jun 2026$266M -14.2%+7.5%0.2%
LGNDLigand Pharmaceuticals IncorporatedJun 2026$156.87M -23.3%+294.1%7.2%
INCYIncyte CorporationJun 2026$104.39M +684.1%-28.9%1.3%
GMABGenmab A/SJun 2026$36M +2.9%-23.8%0.3%
AMGNAmgen Inc.Jun 2026$0 -100.0%—0.0%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$0 -100.0%+50.1%0.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
Peer median (excluding LGND) $104.39M-11.3%-7.3%0.3%

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents19.52M45.01M22.95M72.31M174.93M
Short-term Investments321.59M166.86M147.36M183.86M558.59M
Net Receivables91.65M35.04M39.31M42.45M61.05M
Inventory27.33M13.29M23.97M14.11M9.13M
Other Current Assets4.67M2.27M2.66M16.9M28.58M
Total Current Assets464.75M263.6M237.43M331.56M832.27M
Property, Plant & Equipment (Net)32.6M27.49M25.06M24.81M10.79M
Goodwill105.67M105.67M103.37M105.25M101.54M
Intangible Assets386.8M352.64M299.61M266.65M422.32M
Long-term Investments03M111.61M10.91M183.58M
Tax Assets35.73M8.53M214K72K8.35M
Other Non-current Assets272.03M1.74M9.92M202.53M1.79M
Total Non-current Assets832.84M499.07M549.79M610.22M728.37M
Total Assets1.3B762.67M787.22M941.77M1.56B
Account Payables8.4M5.31M2.43M5.23M3.24M
Short-term Debt076.7M000
Tax Payables0001.2M1.24M
Deferred Revenue654K976K1.84M1.9M621K
Other Current Liabilities22.57M6.26M4.94M(3.2M)6.81M
Total Current Liabilities41.67M98.81M16.78M37.11M37.45M
Long-term Debt320.72M000446.19M
Deferred Tax Liabilities30.86M30.62M31.62M32.52M52.61M
Deferred Revenue (Non-current)044K15.14M00
Other Non-current Liabilities80.94M25.38M17M35.88M2.97M
Total Non-current Liabilities434.77M66.37M69.52M74.22M505.98M
Total Liabilities476.43M165.18M86.3M111.34M543.43M
Common Stock17K17K18K20K20K
Retained Earnings449.09M450.86M503.02M498.98M608.09M
Accumulated OCI(917K)(984K)(817K)(5.94M)8.46M
Other Stockholders Equity00000
Minority Interest00000
Total Equity821.16M597.49M700.91M830.44M1.02B
Total Debt324.39M87.75M6.17M7.11M451.49M
Net Debt304.86M42.74M(16.79M)(65.2M)276.56M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.